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Edited by Ulrike KutayAbstract Ribosomal S6 kinase 2 (S6K2) acts downstream of
the mammalian target of rapamycin (mTOR). Here, we show
that some S6K2 localize at the centrosome throughout the cell
cycle. S6K2 is found in the pericentriolar area of the centrosome.
S6K2 centrosomal localization is unaﬀected by serum with-
drawal or treatment with rapamycin, wortmannin, U0126, or
phorbol-12-myristate-13-acetate (PMA). Unlike S6K2, S6
kinase 1 (S6K1) does not localize at the centrosome, suggesting
the two kinases may also have nonoverlapping functions. Our
data suggest that centrosomal S6K2 may have a role in the phos-
phoinositide-3-kinase (PI3K)/Akt/mTOR signaling pathway that
has also been detected in the centrosome.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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c-Tubulin1. Introduction
Rapamycin is an immunosuppressant used in organ trans-
plantation and more recently in some cardiac and anti-cancer
therapies [1]. Rapamycin blocks or delays cell proliferation of
many diﬀerent cell types [1]. Its mammalian cellular target,
mTOR, is a regulator of nutrient- and growth factor-sensing
mechanisms and controls many cellular processes such as
translation, cell cycle progression, cell size regulation, tran-
scription, and cytoskeleton regulation [1]. Several proteins
are activated downstream of mTOR, two of which are S6K1
and S6K2. S6K1 and S6K2 both phosphorylate the 40S ribo-
somal subunit protein S6 [2,3], a process that was thought to
increase translation of mRNAs with a 5 0-terminus oligopyrim-
idine tract (5 0TOP mRNA). Many 5 0TOP mRNAs encode the
translational machinery, leading to an increase in cellular pro-
tein synthesis capacity in preparation for cell division. How-
ever, recent studies showed that cells from S6K1 and S6K2
double knockout mice have impaired S6 phosphorylation but
maintain mTOR-dependent 5 0TOP mRNA translation, putt-
ing into question the function of S6 phosphorylation by
S6K1 and S6K2 [2]. S6K1, but not S6K2, regulates cell size;
mice lacking S6K1 have smaller cells and this cannot be com-
pensated by the presence of S6K2 [4]. The full biological func-Abbreviations: S6K1; ribosomal S6 kinase 1; S6K2; ribosomal S6
kinase 2; mTOR; mammalian target of rapamycin
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doi:10.1016/j.febslet.2007.07.047tions of S6K2 are unknown at this time. Understanding how
these signaling molecules contribute to mTOR function would
yield better insights into the mechanism of cell growth and/or
proliferation.
S6K2 was initially identiﬁed as a homolog of S6K1 [4–8]. Evi-
dence points to some common functions shared by the two;
activities of both are regulated by the same upstream activating
pathways such as mTOR, PI3K, andMEK pathways, and both
S6K1 and S6K2 phosphorylate S6 [2–8]. However, several lines
of evidence suggest that the two kinases have diﬀerential regu-
lation and may have non-overlapping cellular function(s). The
non-catalytic domains of the two kinases are distinct, andmuta-
tional studies show that equivalent mutants in the two kinases
do not always behave the same [3,9–11], and that the MEK
pathway plays a more important role for regulation of S6K2
than that of S6K1 through the C terminus of S6K2 [9,10].
The phenotypes of S6K1-null and S6K2-null mice are diﬀerent
in that only S6K1 plays a role in cell size regulation, indicating
diﬀerential cellular functions for the two [2]. S6K1 has at least
one substrate, SKAR, that is not phosphorylated by S6K2, sug-
gesting that the two kinases have distinct subsets of substrates
[12]. The full spectrum of S6K2 substrates is yet to be identiﬁed.
There have been reports showing that S6K2 is a nuclear pro-
tein with nuclear localization signals [4,7] and that the kinase
may shuttle to the cytoplasm upon PMA stimulation [13].
There have also been reports of S6K2 staining both cytoplas-
mic and nuclear compartments in human tissues [14–16]. Some
of these studies have noted that S6K2 is seen in a punctate pat-
tern, and in order to further extend this ﬁnding, and in order to
also better elucidate possible cellular function of S6K2, we set
out to assess whether S6K2 co-localizes to any known subcel-
lular components.
In this report, we show that a fraction of S6K2 is found in
the centrosome in all cell cycle stages. S6K2 localization to
the centrosome is not inhibited by serum-starvation or treat-
ment with rapamycin, wortmannin, U0126, or PMA. Interest-
ingly, unlike S6K2, S6K1 does not localize to the centrosome.
Finally, we show that S6K2 is a pericentriolar rather than a
core centrosomal protein. Our study opens a possibility that
the mTOR signaling pathway may also play a role in cytoskel-
eton regulation and/or cell division processes.2. Materials and methods
2.1. Cell culture and transfection
HeLa cells or RPE-1 cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum,
penicillin (250 U/ml), streptomycin (250 lg/ml), and L-glutamineblished by Elsevier B.V. All rights reserved.
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RPMI media supplemented in the same manner as above. When re-
quired, cells were treated with rapamycin (20 ng/ml), wortmannin
(50 nM), U0126 (10 lM), or PMA (20 ng/ml) (all from Calbiochem)
for 30 min. Mouse myoblasts from wild type or S6K1/S6K2 double-
knockout mice (kind gifts from Dr. M. Pende, INSERM, Paris) [17]
were cultured in DMEM-F12 media containing 20% fetal calf serum,
2% Ultroser G, penicillin (250 U/ml), streptomycin (250 lg/ml), and
L-glutamine (292 lg/ml) at 37 C with 5.5% CO2. RPE-1 cells were
transfected with a GFP-centrin 1 construct (a kind gift from Dr. M.
Bornens, Institut Curie, Paris) using FuGene (Roche) per manufac-
turer’s instructions.
2.2. Immunoﬂuorescence
HeLa cells grown on coverslips were either ﬁxed in cold methanol or
in 2% paraformaldehyde and permeabilized in cold methanol. Soluble
proteins were extracted with CSK buﬀer with Triton X-100 as previ-
ously described [18] for Fig. 1A; the rest of the ﬁgures used no tritonS6K2 DAPI
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Fig. 1. S6K2 co-localizes to the centrosome in HeLa cells. (A) Exponentially g
for S6K2 using 07-173. DNA was stained with DAPI. (B) HeLa cells were ﬁ
and with 07-173 (i) or 167-4 (ii) anti-S6K2 antibodies (red). (C) M-phase HeLa
(D) RPE-1 cells were stained with CTR453 (red), or167-4 (green), and DNA
taken and merged for B and C. Bar, 10 lm for A-C, 20 lm for D.extraction. RPE-1 cells were ﬁxed with cold methanol. Primary anti-
bodies: 07-173 sheep anti-S6K2 antibody (Upstate Biotechnology);
167-4 rabbit polyclonal antiserum to S6K2 (a kind gift from Dr. J. Ble-
nis, Harvard Medical School); sc230 anti-S6K1 antibody (Santa Cruz);
anti-c tubulin mAb and CTR453, a monoclonal antibody against
AKAP450 (both gifts from Dr. M. Bornens) [19]. Secondary antibod-
ies: RRX-conjugated anti-rabbit IgG; RRX-conjugated anti-sheep
IgG; FITC-conjugated anti-mouse IgG; Cy3-conjugated anti-mouse
Ig (all from Jackson ImmunoResearch Lab); and Alexa 488-conju-
gated anti-rabbit Ig (Molecular Probes). DNA was stained with
0.1 lg/ml 4 0,6-diamidino-2-phenylindole (DAPI; Sigma). Confocal
and conventional epiﬂuorescence microscopy was performed as previ-
ously described [18].
2.3. Immunoblot
Cell lysates were immunoblotted as previously described [3]. Cell ly-
sates were adjusted to have equal protein concentrations prior to gel
loading. Primary antibodies: 07-173; 167-4; MP CT anti-S6K2 mousemerge
merge
merge
S6K2+
CTR453
S6K2+
CTR453+
DAPI
rowing HeLa cells were ﬁxed, extracted with Triton X-100, and stained
xed with methanol and co-stained with anti-c-tubulin antibody (green)
cells were co-stained with anti-c-tubulin (green) and with 07-173 (red).
was stained with DAPI. Confocal laser images of the same cell were
4060 R. Rossi et al. / FEBS Letters 581 (2007) 4058–4064mAb (gift from Dr. M. Pende) [2]; C3 rabbit anti-S6K1 antibody (gift
from Dr. J. Blenis); anti-a-tubulin antibody (Sigma); anti-c-tubulin
antibody (gift form Dr. M. Bornens) [19]; anti-phospho-Erk antibody;
anti-phospho-Akt substrate antibody; anti-phospho-S6 antibody; and
anti-Erk antibody (last four from Cell Signaling Technology).
2.4. Puriﬁcation of centrosome
Centrosomeswere puriﬁed fromKE-37 cells and immunoﬂuorescence
on puriﬁed centrosomes was carried out as previously described [20].3. Results
We carried out immunoﬂuorescence on HeLa cells to study
subcellular localization of endogenous S6K2. We used anti-
bodies to endogenous S6K2 rather than using ectopically-A B
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Fig. 2. Further veriﬁcation of S6K2 localization to the centrosome. (A) Puriﬁ
MP CT anti-S6K2 antibodies. (B) Puriﬁed centrosomes or total cell lysates w
marker, or against Erk, which is not found in the centrosome. Puriﬁed centros
anti-c-tubulin antibody (green) (bottom panel). Bar, 20 lm. (C) Puriﬁed c
Myoblast cells isolated from wild-type (WT) or S6K1/2 double knockout (KO
antibodies (green). Bar, 20 lm. (E) Cell lysates from wild-type or knockout mexpressed ﬂuorescent S6K2 in order to eliminate potential
complications from over-expression or epitope interference.
For our immunoﬂuorescence studies we used two diﬀerent
anti-S6K2 antibodies, 07-173 sheep anti-S6K2 antibody and
167-4 rabbit anti-S6K2 antibody [5]. When asynchronously-
growing HeLa cells were stained with 07-173, we observed a
speckled pattern both in the nucleus and the cytoplasm with
a dot of S6K2 accumulating within the cytoplasm, located near
the nucleus (Fig. 1A). During mitosis the protein was found in
the cell body and did not co-localize with the condensed chro-
mosomes (Fig. 1A). Similar data were obtained with 167-4
(data not shown and Fig. 1B).
The dot-like structure observed in the cytoplasm (Fig. 1A)
was reminiscent of the centrosome. To see if S6K2 co-localizes
with the centrosome we performed a confocal microscopyγ−tubulin: green
CTR453: red
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ere immunoblotted with an antibody against c-tubulin, a centrosome
omes were also ﬁxed onto a coverslip and stained with CTR453 (red) or
entrosomes or total cell lysates were immunoblotted for S6K1. (D)
) mice were stained with CTR453 (red) and 167-4 or 07-173 anti-S6K2
yoblasts were immunoblotted for S6K2 or a-tubulin (loading control).
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and with an antibody against c-tubulin, a centrosome marker.
Fig. 1B shows that S6K2 and c-tubulin indeed co-localized at
the centrosome. This was observed whether we used 07-173 (i)
or 167-4 (ii) anti-S6K2 antibody. During mitosis S6K2 also
associated with the mitotic asters (Fig. 1C), indicating that
S6K2 also associates with the centrosome components during
mitosis. We next veriﬁed localization of S6K2 to the centro-
some in another cell type. RPE-1 cells, a human retinal epithe-
lial cell line, were stained using 167-4 anti-S6K2 antibody and
CTR453, a centrosome-speciﬁc monoclonal antibody against
AKAP450 protein [21]. Fig. 1D shows that S6K2 is localized
throughout the cell in RPE-1 cells, and that a fraction of
S6K2 accumulated to the centrosome in RPE-1 cells as well.
Equivalent results were seen when HEK293 cells were used
(data not shown).
Next, we veriﬁed centrosomal localization of S6K2 using
biochemical methods. Centrosomes were puriﬁed via sucrose
gradient and analyzed by immunoblotting with antibodies
against S6K2. We observe that S6K2 is detected in puriﬁed
centrosomes when immunoblotted with anti-S6K2 antibodies,
whether we use 167-4 or MP CT antibody (Fig. 2A). Fig. 2B
shows that the puriﬁed centrosome was indeed enriched in c-
tubulin, a centrosome-speciﬁc marker, but did not contain
non-centrosomal protein such as Erk. An aliquot of the puri-
ﬁed centrosomes used in immunoblotting was also stained with
CTR453 and anti-c-tubulin antibodies in order to verify via
immunoﬂuorescence that centrosome puriﬁcation was indeed
successful (Fig. 2B, bottom panel). We also asked whether cen-
trosome localization is unique to S6K2 or can be generalized to
both S6K1 and S6K2. When we immunoblotted puriﬁed cen-
trosomes with an antibody against S6K1, we did not observe
any S6K1, indicating that only S6K2, and not S6K1, co-local-
izes to the centrosome (Fig. 2C). The lack of S6K1 in the cen-
trosome also indicates that our centrosome preparation was
free of contaminating cytosolic or nuclear proteins, as S6K1
is shown to reside in both nucleus and cytosol [22]. Our data
indicate that S6K2, but not S6K1, is co-puriﬁed with the cen-
trosome.
In order to further verify that immunoﬂuorescence of cen-
trosomal S6K2 in Fig. 1 was due to S6K2-speciﬁc binding of
the antibodies and not due to cross-reaction with another pro-
tein, we used cells from S6 kinase knockout mice in immuno-
ﬂuorescence studies. We cultured myoblasts from wild-type or
S6K1/S6K2 double-knockout mice and carried out immuno-
ﬂuorescence using CTR453 and anti-S6K2 antibodies
(Fig. 2D). In cultured myoblasts from wild-type mice we again
observed the dot-like staining of S6K2 at the centrosome, and
this was seen with both anti-S6K2 antibodies. On the contrary,
knockout cells showed no centrosomal localization of S6K2.
We observed dimmed homogenous staining in knockout cells,
which indicates that both antibodies have a low-level non-spe-
ciﬁc background staining. Immunoblotting cell lysates from
the knockout and wild-type myoblasts showed that the knock-
out cells are indeed lacking S6K2 (Fig. 2E). Our data indicate
that the dot-like centrosomal staining we observe with both
167-4 and 07-173 anti-S6K2 antibodies are speciﬁc to S6K2
since such staining disappears when cells do not express S6K2.
In order to characterize the conditions in which S6K2 local-
izes to the centrosome, we treated RPE-1 cells with various
stimuli or inhibitors and assessed S6K2 centrosomal localiza-
tion using immunoﬂuorescence. First, we withdrew serumfrom the growth media of RPE-1 cells for 16 h and carried
out immunoﬂuorescence. Fig. 3A shows that co-localization
of S6K2 with the centrosome was still preserved whether the
cells were serum-starved or cultured in serum-containing med-
ia. Cell lysates from the serum-starved vs. serum-containing
culture conditions were immunoblotted with anti-phospho-
Erk antibody to show that cells were indeed serum-starved.
We next assessed whether known upstream regulators of
S6K2 activity such as mTOR, PI3K, and MEK play a role
in centrosomal localization of S6K2. We used three diﬀerent
inhibitors: rapamycin, a pharmacologic inhibitor of mTOR;
wortmannin, an inhibitor of the PI3K pathway; and U0126,
an inhibitor of the Map kinase kinase (MEK) pathway. When
RPE-1cells were treated with rapamycin (Fig. 3B), wortman-
nin (Fig. 3C), or U0126 (Fig. 3D), centrosomal localization
of S6K2 was still observed. Immunoblotting of cell lysates
from each condition showed that inhibitors functioned prop-
erly (Fig. 3B–D right panels): rapamycin inhibited phosphory-
lation of S6, a downstream event of mTOR/S6 kinases;
wortmannin reduced the activity of Akt, a downstream target
of PI3K, as shown by reduction of phosphorylation of sub-
strates of Akt; and U0126 inhibited phosphorylation of Erk,
a target of MEK. We conclude that inhibition of mTOR,
PI3K, and MEK pathways had no eﬀect on S6K2 localization
to the centrosome.
We next assessed whether PMA plays a role in S6K2 centro-
somal localization. It has been shown that S6K2 can shuttle to
the cytoplasm when stimulated with PMA [13]. We serum-
starved RPE-1 cells and then treated them with or without
PMA for 30 min. We observed in serum-starved cells both
cytoplasmic and nuclear staining of S6K2 as seen in Fig. 3A,
but when cells were stimulated with PMA, staining of S6K2
intensiﬁes in the cytosol, indicating that S6K2 migrates to
the cytosol upon PMA treatment (Fig. 3E). Our data conﬁrm
the previous ﬁndings that PKC regulates cytosolic shuttling of
S6K2 [13]. However, we observed no change in centrosomal
localization of S6K2 with PMA treatment.
We next assessed whether localization of S6K2 is a cell cycle-
dependent event. We have already shown that during mitosis
S6K2 is found in the spindle poles (Fig. 1C). We asked whether
S6K2 is found in the centrosome in G1, S or G2 phases. RPE-1
cells were transfected with a construct for GFP-centrin 1 and
stained with 167-4. Centrin 1 can speciﬁcally stain each centri-
ole and therefore the number of centrioles as well as the dis-
tance between them can be used to determine the cell cycle
stage of a given cell. Fig. 4A shows that S6K2 localizes to
the centrosome in G1, S and G2 phases of the cell cycle in
RPE-1 cells. Finally, we carried out immunoﬂuorescence on
puriﬁed centrosomes using CTR453 and 167-4. Fig. 4B con-
ﬁrms that S6K2 is found in the biochemically-puriﬁed centro-
some as well. The staining shows that the S6K2 and CTR453
overlap but not completely, indicating that S6K2 is not a core
integral centrosomal protein but rather is found in the peri-
centriolar area.4. Discussion
In this paper, we show for the ﬁrst time that S6K2, but not
S6K1, localizes to the centrosome throughout the cell cycle,
more speciﬁcally to the pericentriolar area of the centrosome
complex. There are several implications to our ﬁndings. First,
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Fig. 3. Characterization of centrosomal localization of S6K2. (A) RPE-1 cells were cultured in serum-free media for 16 h () or in media containing
fetal calf serum (+) and stained with CTR453 (red) or 167-4 (green). Right panels show an immunoblot of lysates for phospho-Erk or a-tubulin
(loading control). (B-D) RPE-1 cells cultured in serum-containing complete media were treated without () or with (+) rapamycin (B), wortmannin
(C), or U0126 (D) for 30 minutes and stained with CTR453 (red) or167-4 (green). Right panels show cell lysates from the experiments immunoblotted
with antibodies against phospho-S6 (B), phospho-Akt substrates (C), or phospho-Erk (D). a-Tubulin immunoblots are shown for loading control.
(E) RPE-1 cells were cultured in serum-free media for 16 h () and then treated with PMA (+) for 30 min. and stained with CTR453 (red) or 167-4
(green). Right panels show an immunoblot with anti-phospho-Erk or a-tubulin (loading control). Bars: 20 lm.
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probably have non-overlapping cellular functions, and that,
although both kinases phosphorylate the S6 protein, theymay also have distinct function and substrates. Second, there
have been several recent papers showing that proteins in the
PI3K/mTOR signaling pathway such as Akt [23,24], TSC1
S6K2GFP-Centrin1 Merge
G1 and G2 phases
S6K2
S phase
Merge
MergeS6K2 CTR453
A
B
1
2
1=G1 phase
2=G2 phase
GFP-Centrin1
Fig. 4. S6K2 is found at the centrosome throughout the cell cycle and is found in the pericentriolar area. (A) RPE-1 cells were transfected with GFP-
centrin 1 and stained with 167-4 (red). (B) Puriﬁed centrosomes were ﬁxed onto coverslips and stained with CTR453 (red) and 167-4 (green). Bar,
20 lm.
R. Rossi et al. / FEBS Letters 581 (2007) 4058–4064 4063[25], and PI3K [26,27] localize to the centrosome. PI3K/mTOR
pathway may play a yet-to-be-deﬁned role in broader cytoskel-
eton regulation; most recently two proteins in the TOR path-
way, Raptor and RheB, have been shown to play a role in
mitotic spindle assembly in Drosophila [28]. We now have evi-
dence that S6K2, one of the downstream targets of the PI3K/
mTOR pathway, is also found in the centrosome, whereas an-
other target, S6K1, does not. The full biological function for
localization of the PI3K/mTOR pathway to the centrosome
remains to be determined, although our data show that it is
unlikely that the centrosome-relevant signaling from this path-
way would be exerted via S6K1. Astrinidis et al. showed that
TSC1 localizes to the centrosome and plays a role in centro-
some duplication via the mTOR pathway [25]. It would be
interesting to determine if S6K2 plays a role in regulation of
centrosome duplication by TSC1.
Since S6K2 is a kinase it could be assumed that it phosphor-
ylates a yet-to-be-identiﬁed substrate(s) at the centrosome that
may aﬀect centrosomal function. Identiﬁcation of possible cen-
trosomal substrates for S6K2 is underway. Current data sug-
gest that S6K2 is not likely to be an absolute requirement
for centrosome function; treatment of RPE-1 cells with rapa-
mycin up to 6 h did not alter the number or gross phenotype
of the centrosome (Fig. 3B and data not shown), and S6K2
knockout mice do not have an obvious phenotype, suggesting
that, if S6K2 plays a role in centrosome function, it is likely to
be more subtle and readily compensated by another protein. It
is also possible that S6K2 migrates to the centrosome not to
aﬀect centrosome’s function but rather in order to receive cer-
tain signals from the centrosomal complex. This opens an
interesting possibility that cytoskeletal regulation may play a
role in S6K2 function. Our data suggest a possible interplaybetween centrosome function and the mTOR pathway. Fur-
ther investigation is underway to delineate the detailed nature
of this interplay.
Acknowledgements: We thank Drs. M. Pende, M. Bornens, J. Blenis,
and D. Fruman for the reagents and/or discussions. We also thank
C. Celati and A. M. Tassin for their help. We thank the Immunolocal-
ization Service of IGM, Pavia and Centro Grandi Strumenti of the
University of Pavia for the microscopy facilities. This work was sup-
ported by grants from National Institute of Health (MBRS SCORE,
Grant No. 2 S06 GM063119-05) and HHMI (Grant No. 52002663)
to K.L.-F. and by a grant from Fondazione Cariplo to A.M.References
[1] Fingar, D.C. and Blenis, J. (2004) Target of rapamycin (TOR): an
integrator of nutrient and growth factor signals and coordinator
of cell growth and cell cycle progression. Oncogene 23, 3151–
3171.
[2] Pende, M. et al. (2004) S6K1(/)/S6K2(/) mice exhibit
perinatal lethality and rapamycin-sensitive 5 0-terminal oligopyr-
imidine mRNA translation and reveal a mitogen-activated protein
kinase-dependent S6 kinase pathway. Mol. Cell Biol. 24, 3112–
3124.
[3] Phin, S., Kupferwasser, D., Lam, J. and Lee-Fruman, K.K. (2003)
Mutational analysis of ribosomal S6 kinase 2 shows diﬀerential
regulation of its kinase activity from that of ribosomal S6 kinase
1. Biochem. J. 373, 583–591.
[4] Shima, H., Pende, M., Chen, Y., Fumagalli, S., Thomas, G. and
Kozma, S.C. (1998) Disruption of the p70(s6k)/p85(s6k) gene
reveals a small mouse phenotype and a new functional S6 kinase.
Embo J. 17, 6649–6659.
[5] Lee-Fruman, K.K., Kuo, C.J., Lippincott, J., Terada, N. and
Blenis, J. (1999) Characterization of S6K2, a novel kinase
homologous to S6K1. Oncogene 18, 5108–5114.
4064 R. Rossi et al. / FEBS Letters 581 (2007) 4058–4064[6] Gout, I., Minami, T., Hara, K., Tsujishita, Y., Filonenko, V.,
Waterﬁeld, M.D. and Yonezawa, K. (1998) Molecular cloning
and characterization of a novel p70 S6 kinase, p70 S6 kinase beta
containing a proline-rich region. J. Biol. Chem. 273, 30061–30064.
[7] Koh, H. et al. (1999) Cloning and characterization of a nuclear
S6 kinase, S6 kinase-related kinase (SRK) a novel nuclear target
of Akt. Oncogene 18, 5115–5119.
[8] Saitoh, M., ten Dijke, P., Miyazono, K. and Ichijo, H. (1998)
Cloning and characterization of p70(S6K beta) deﬁnes a novel
family of p70 S6 kinases. Biochem. Biophys. Res. Commun. 253,
470–476.
[9] Martin, K.A., Schalm, S.S., Richardson, C., Romanelli, A.,
Keon, K.L. and Blenis, J. (2001) Regulation of ribosomal S6
kinase 2 by eﬀectors of the phosphoinositide 3-kinase pathway. J.
Biol. Chem. 276, 7884–7891.
[10] Martin, K.A., Schalm, S.S., Romanelli, A., Keon, K.L. and
Blenis, J. (2001) Ribosomal S6 kinase 2 inhibition by a potent C-
terminal repressor domain is relieved by mitogen-activated
protein-extracellular signal-regulated kinase kinase-regulated
phosphorylation. J. Biol. Chem. 276, 7892–7898.
[11] Minami, T. et al. (2001) Distinct regulatory mechanism for p70
S6 kinase beta from that for p70 S6 kinase alpha. Genes Cells 6,
1003–1015.
[12] Richardson, C.J., Broenstrup, M., Fingar, D.C., Julich, K., Ballif,
B.A., Gygi, S. and Blenis, J. (2004) SKAR is a speciﬁc target of S6
kinase 1 in cell growth control. Curr. Biol. 14, 1540–1549.
[13] Valovka, T. et al. (2003) Protein kinase C phosphorylates
ribosomal protein S6 kinase betaII and regulates its subcellular
localization. Mol. Cell Biol. 23, 852–863.
[14] Filonenko, V.V., Tytarenko, R., Azatjan, S.K., Savinska, L.O.,
Gaydar, Y.A., Gout, I.T., Usenko, V.S. and Lyzogubov, V.V.
(2004) Immunohistochemical analysis of S6K1 and S6K2 local-
ization in human breast tumors. Exp. Oncol. 26, 294–299.
[15] Lyzogubov, V.V. et al. (2004) Immunohistochemical analysis of
S6K1 and S6K2 expression in endometrial adenocarcinomas.
Exp. Oncol. 26, 287–293.
[16] Savinska, L.O. et al. (2004) Immunohistochemical analysis of
S6K1 and S6K2 expression in human breast tumors. Eksp Onkol.
26, 24–30.
[17] Ohanna, M. et al. (2005) Atrophy of S6K1(/) skeletal muscle
cells reveals distinct mTOR eﬀectors for cell cycle and size control.
Nat. Cell Biol. 7, 286–294.[18] Lidonnici, M.R. et al. (2004) Subnuclear distribution of the
largest subunit of the human origin recognition complex during
the cell cycle. J. Cell Sci. 117, 5221–5231.
[19] Tassin, A.M., Celati, C., Moudjou, M. and Bornens, M. (1998)
Characterization of the human homologue of the yeast spc98p
and its association with gamma-tubulin. J. Cell Biol. 141, 689–
701.
[20] Moudjou, M. and Bornens, M. (1994) Cell Biology: A Laboratory
Handbook, Academic Press, Inc., pp. 595–604.
[21] Bailly, E., Doree, M., Nurse, P. and Bornens, M. (1989) p34cdc2
is located in both nucleus and cytoplasm; part is centrosomally
associated at G2/M and enters vesicles at anaphase. Embo J. 8,
3985–3995.
[22] Coﬀer, P.J. and Woodgett, J.R. (1994) Diﬀerential subcellular
localisation of two isoforms of p70 S6 protein kinase. Biochem.
Biophys. Res. Commun. 198, 780–786.
[23] Kalous, J., Solc, P., Baran, V., Kubelka, M., Schultz, R.M. and
Motlik, J. (2006) PKB/AKT is involved in resumption of meiosis
in mouse oocytes. Biol. Cell 98, 111–123.
[24] Wakeﬁeld, J.G., Stephens, D.J. and Tavare, J.M. (2003) A role for
glycogen synthase kinase-3 in mitotic spindle dynamics and
chromosome alignment. J. Cell Sci. 116, 637–646.
[25] Astrinidis, A., Senapedis, W. and Henske, E.P. (2006) Hamartin,
the tuberous sclerosis complex 1 gene product, interacts with
polo-like kinase 1 in a phosphorylation-dependent manner. Hum.
Mol. Genet. 15, 287–297.
[26] Kapeller, R., Toker, A., Cantley, L.C. and Carpenter, C.L. (1995)
Phosphoinositide 3-kinase binds constitutively to alpha/beta-
tubulin and binds to gamma-tubulin in response to insulin. J.
Biol. Chem. 270, 25985–25991.
[27] Delaval, B., Letard, S., Lelievre, H., Chevrier, V., Daviet, L.,
Dubreuil, P. and Birnbaum, D. (2005) Oncogenic tyrosine kinase
of malignant hemopathy targets the centrosome. Cancer Res. 65,
7231–7240.
[28] Goshima, G., Wollman, R., Goodwin, S.S., Zhang, N., Scholey,
J.M., Vale, R.D. and Stuurman, N. (2007) Genes required for
mitotic spindle assembly in Drosophila S2 cells. Science 316, 417–
421.
